GD |
Thyroid |
Hypermethylation of LCK, CD247, ZAP70, CD3D, CD3E, CD3G, CTLA4 and PDCD1, LAX1 and SLA2, and CD8A |
Human |
Disturbing the activation and regulation of CD8+ T cells |
(123) |
GD |
Thyroid |
Reduced H3K4me3 and H3K27ac of CD247, CD3E, CD3G, LCK, ZAP70, and CTLA4 |
Human |
Involved in the activation of CD8+ T cells |
(123) |
GD |
Thyroid |
Reduced miRNA-200a_1 and miRNA-200a2* |
Human |
Assisting CD8+ T cells producing thyroid cell-specific antibodies |
(122) |
MS |
CNS |
Hypermethylation of MORN1 |
|
Not mentioned |
(100) |
MS |
CNS |
Increased miR-16, miR-155 and miR-142-3p |
Human |
Inhibiting Treg-suppressive activity |
(124–126) |
SSc |
Skin |
Hypomethylation of IFI44L, IFITM1, MX1, PARP9 |
Human |
Activation of Wnt signaling |
(127, 128) |
T1D |
β cells and pancreas |
Increased miR-29b |
Mice |
Impairing the cytotoxicity of CD8+ T cells |
(129) |
SLE |
Multi-organs |
Hypomethylation of PRF |
Human |
Enhancing the cytotoxicity of CD8+ T cells |
(56, 116) |
SAA |
Hematopoietic cells |
Hypomethylation of LAT |
Mice |
Enhancing the cytotoxicity of CD8+ T cells |
(130) |
SAA |
Hematopoietic cells |
Increased histone H3 acetylation |
Human |
Enhancing the cytotoxicity of CD8+ T cells |
(131) |